Literature DB >> 7708752

Structure, expression, and chromosomal localization of the type I human vasoactive intestinal peptide receptor gene.

S P Sreedharan1, J X Huang, M C Cheung, E J Goetzl.   

Abstract

Vasoactive intestinal peptide (VIP) and other members of the pituitary adenylyl cyclase-activating peptide (PACAP) and secretin neuroendocrine peptide family are recognized with specificity by related G protein-coupled receptors. We report here the cloning, characterization, and chromosomal location of the gene encoding the human type I VIP receptor (HVR1), also termed the type II PACAP receptor. The gene spans approximately 22 kb and is composed of 13 exons ranging from 42 to 1400 bp and 12 introns ranging from 0.3 to 6.1 kb. Primer extension analysis with poly(A)+ RNA from human HT29 colonic adenocarcinoma cells indicated that the transcription initiation site is located at position -110 upstream of the first nucleotide (+1) of the translation start codon, and 75 nt downstream of a consensus CCAAT-box motif. The G+C-rich 5' flanking region contains potential binding sites for several nuclear factors, including Sp1, AP2, ATF, interferon regulatory factor 1, NF-IL6, acute-phase response factor, and NF-kappa B. The HVR1 gene is expressed selectively in human tissues with a relative prevalence of lung > prostate > peripheral blood leukocytes, liver, brain, small intestine > colon, heart, spleen > placenta, kidney, thymus, testis. Fluorescence in situ hybridization localized the HVR1 gene to the short arm of human chromosome 3 (3p22), in a region associated with small-cell lung cancer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7708752      PMCID: PMC42334          DOI: 10.1073/pnas.92.7.2939

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  20 in total

1.  Compilation of vertebrate-encoded transcription factors.

Authors:  S Faisst; S Meyer
Journal:  Nucleic Acids Res       Date:  1992-01-11       Impact factor: 16.971

2.  High-resolution mapping of human chromosome 11 by in situ hybridization with cosmid clones.

Authors:  P Lichter; C J Tang; K Call; G Hermanson; G A Evans; D Housman; D C Ward
Journal:  Science       Date:  1990-01-05       Impact factor: 47.728

3.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Authors:  R K Saiki; D H Gelfand; S Stoffel; S J Scharf; R Higuchi; G T Horn; K B Mullis; H A Erlich
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

Review 4.  Splicing of messenger RNA precursors.

Authors:  R A Padgett; P J Grabowski; M M Konarska; S Seiler; P A Sharp
Journal:  Annu Rev Biochem       Date:  1986       Impact factor: 23.643

5.  A constitutive promoter directs expression of the nerve growth factor receptor gene.

Authors:  A Sehgal; N Patil; M Chao
Journal:  Mol Cell Biol       Date:  1988-08       Impact factor: 4.272

6.  Interferon gamma response region in the promoter of the human DPA gene.

Authors:  Z Yang; M Sugawara; P D Ponath; L Wessendorf; J Banerji; Y Li; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

7.  Induction of the transcription factor IRF-1 and interferon-beta mRNAs by cytokines and activators of second-messenger pathways.

Authors:  T Fujita; L F Reis; N Watanabe; Y Kimura; T Taniguchi; J Vilcek
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

8.  Definition of a tumor suppressor locus within human chromosome 3p21-p22.

Authors:  A M Killary; M E Wolf; T A Giambernardi; S L Naylor
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

Review 9.  VIP: molecular biology and neurobiological function.

Authors:  I Gozes; D E Brenneman
Journal:  Mol Neurobiol       Date:  1989       Impact factor: 5.590

10.  Human vasoactive intestinal peptide1 receptors expressed by stable transfectants couple to two distinct signaling pathways.

Authors:  S P Sreedharan; D R Patel; M Xia; S Ichikawa; E J Goetzl
Journal:  Biochem Biophys Res Commun       Date:  1994-08-30       Impact factor: 3.575

View more
  35 in total

1.  Characterization and use of a rabbit-anti-mouse VPAC1 antibody by flow cytometry.

Authors:  Rebecca J Hermann; Travis Van der Steen; Emilie E Vomhof-Dekrey; Sejaa Al-Badrani; Steve B Wanjara; Jarrett J Failing; Jodie S Haring; Glenn P Dorsam
Journal:  J Immunol Methods       Date:  2011-11-04       Impact factor: 2.303

2.  Pituitary adenylate cyclase-activating polypeptide inhibits transforming growth factor-beta1-induced apoptosis in a human pituitary adenoma cell line.

Authors:  H Oka; L Jin; E Kulig; B W Scheithauer; R V Lloyd
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 3.  Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.

Authors:  Anthony J Harmar; Jan Fahrenkrug; Illana Gozes; Marc Laburthe; Victor May; Joseph R Pisegna; David Vaudry; Hubert Vaudry; James A Waschek; Sami I Said
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

4.  Antisecretory actions of a novel vasoactive intestinal polypeptide (VIP) antagonist in human and rat small intestine.

Authors:  Matthew R Banks; Michael J G Farthing; Patrick Robberecht; David E Burleigh
Journal:  Br J Pharmacol       Date:  2005-04       Impact factor: 8.739

5.  VIP modulates the pro-inflammatory maternal response, inducing tolerance to trophoblast cells.

Authors:  Laura Fraccaroli; Julio Alfieri; Luciana Larocca; Mario Calafat; Valeria Roca; Eduardo Lombardi; Rosanna Ramhorst; Claudia Pérez Leirós
Journal:  Br J Pharmacol       Date:  2009-01       Impact factor: 8.739

Review 6.  A VIP hybrid antagonist: from developmental neurobiology to clinical applications.

Authors:  I Gozes; M Fridkin; D E Brenneman
Journal:  Cell Mol Neurobiol       Date:  1995-12       Impact factor: 5.046

7.  Transcriptomic architecture of the adjacent airway field cancerization in non-small cell lung cancer.

Authors:  Humam Kadara; Junya Fujimoto; Suk-Young Yoo; Yuho Maki; Adam C Gower; Mohamed Kabbout; Melinda M Garcia; Chi-Wan Chow; Zuoming Chu; Gabriella Mendoza; Li Shen; Neda Kalhor; Waun Ki Hong; Cesar Moran; Jing Wang; Avrum Spira; Kevin R Coombes; Ignacio I Wistuba
Journal:  J Natl Cancer Inst       Date:  2014-02-22       Impact factor: 13.506

8.  Molecular cloning and characterization of two pig vasoactive intestinal polypeptide receptors (VPAC1-R and VPAC2-R).

Authors:  Xiaping He; Fengyan Meng; Yajun Wang; Juan Li
Journal:  DNA Cell Biol       Date:  2014-02-12       Impact factor: 3.311

9.  Developmental upregulation of human parathyroid hormone (PTH)/PTH-related peptide receptor gene expression from conserved and human-specific promoters.

Authors:  J D Bettoun; M Minagawa; G N Hendy; L C Alpert; C G Goodyer; D Goltzman; J H White
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

10.  Vasoactive intestinal peptide inhibits human small-cell lung cancer proliferation in vitro and in vivo.

Authors:  K Maruno; A Absood; S I Said
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.